November 27, 2023 08:31 PM ESTUpdated 06:38 AM

Aldeyra's dry eye drug gets a rejection from the FDA

Katherine Lewin

News Reporter

Kyle LaHucik

Senior Reporter

The FDA handed down a complete response letter to Aldeyra Therapeutics for its dry eye disease drug reproxalap, following months of speculation about whether the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aldeyra's dry eye drug gets a rejection from the FDA

Katherine Lewin

News Reporter

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Aldeyra's dry eye drug gets a re­jec­tion from the FDA

News Reporter

Senior Reporter

Sign up to read this article for free.

Aldeyra's dry eye drug gets a rejection from the FDA